...
search icon
ifrx-img

InflaRx N.V., Common Stock

IFRX

NSQ

$2

-$0.7

(-25.93%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$117.77M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
4.57M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.58
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.17 L
$2.81 H
$2

About InflaRx N.V., Common Stock

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIFRXSectorS&P500
1-Week Return-19.03%-0.03%1.53%
1-Month Return-14.53%4.56%4.75%
3-Month Return-1.48%1.29%2.77%
6-Month Return48.15%-3.54%12.18%
1-Year Return36.05%1.59%22.34%
3-Year Return-36.91%13.55%38.91%
5-Year Return-41%40.85%80.7%
10-Year Return-86.66%105.52%190.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue----63.09K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue661.25K664.03K696.14K585.85K532.26K[{"date":"2019-12-31","value":94.99,"profit":true},{"date":"2020-12-31","value":95.39,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.16,"profit":true},{"date":"2023-12-31","value":76.46,"profit":true}]
Gross Profit(661.25K)(664.03K)(696.14K)(585.85K)(469.17K)[{"date":"2019-12-31","value":-66124500,"profit":false},{"date":"2020-12-31","value":-66403000,"profit":false},{"date":"2021-12-31","value":-69613700,"profit":false},{"date":"2022-12-31","value":-58585200,"profit":false},{"date":"2023-12-31","value":-46917300,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)(743.67%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":-743.67,"profit":false}]
Operating Expenses56.77M33.94M47.63M32.24M44.44M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":59.79,"profit":true},{"date":"2021-12-31","value":83.91,"profit":true},{"date":"2022-12-31","value":56.79,"profit":true},{"date":"2023-12-31","value":78.28,"profit":true}]
Operating Income(56.77M)(33.94M)(47.63M)(32.24M)(44.91M)[{"date":"2019-12-31","value":-5676817300,"profit":false},{"date":"2020-12-31","value":-3394280400,"profit":false},{"date":"2021-12-31","value":-4763481600,"profit":false},{"date":"2022-12-31","value":-3223786600,"profit":false},{"date":"2023-12-31","value":-4490809500,"profit":false}]
Total Non-Operating Income/Expense6.33M694.89K2.05M3.06M5.59M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":10.97,"profit":true},{"date":"2021-12-31","value":32.3,"profit":true},{"date":"2022-12-31","value":48.39,"profit":true},{"date":"2023-12-31","value":88.22,"profit":true}]
Pre-Tax Income(53.25M)(33.98M)(45.63M)(29.48M)(42.67M)[{"date":"2019-12-31","value":-5325481700,"profit":false},{"date":"2020-12-31","value":-3398361400,"profit":false},{"date":"2021-12-31","value":-4563006000,"profit":false},{"date":"2022-12-31","value":-2948461000,"profit":false},{"date":"2023-12-31","value":-4266752900,"profit":false}]
Income Taxes(3.51M)26.00K24.77K(2.44M)(1.00)[{"date":"2019-12-31","value":-13512.91,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":95.26,"profit":true},{"date":"2022-12-31","value":-9393.45,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(49.74M)(34.01M)(45.65M)(27.04M)(42.67M)[{"date":"2019-12-31","value":-4974146100,"profit":false},{"date":"2020-12-31","value":-3400961400,"profit":false},{"date":"2021-12-31","value":-4565482800,"profit":false},{"date":"2022-12-31","value":-2704231300,"profit":false},{"date":"2023-12-31","value":-4266752800,"profit":false}]
Income From Continuous Operations(53.25M)(33.98M)(45.63M)(29.48M)(34.76M)[{"date":"2019-12-31","value":-5325481700,"profit":false},{"date":"2020-12-31","value":-3398361400,"profit":false},{"date":"2021-12-31","value":-4563005900,"profit":false},{"date":"2022-12-31","value":-2948461100,"profit":false},{"date":"2023-12-31","value":-3476365900,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(49.74M)(34.01M)(45.65M)(27.04M)(42.67M)[{"date":"2019-12-31","value":-4974146100,"profit":false},{"date":"2020-12-31","value":-3400961400,"profit":false},{"date":"2021-12-31","value":-4565482800,"profit":false},{"date":"2022-12-31","value":-2704231300,"profit":false},{"date":"2023-12-31","value":-4266752900,"profit":false}]
EPS (Diluted)(2.05)(1.27)(1.10)(0.67)(0.79)[{"date":"2019-12-31","value":-205,"profit":false},{"date":"2020-12-31","value":-127,"profit":false},{"date":"2021-12-31","value":-110,"profit":false},{"date":"2022-12-31","value":-67,"profit":false},{"date":"2023-12-31","value":-79,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IFRX
Cash Ratio 4.17
Current Ratio 5.31
Quick Ratio 4.61

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IFRX
ROA (LTM) -25.80%
ROE (LTM) -62.07%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IFRX
Debt Ratio Lower is generally better. Negative is bad. 0.18
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.82

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IFRX
Trailing PE NM
Forward PE NM
P/S (TTM) 698.92
P/B 1.74
Price/FCF NM
EV/R 329.93
EV/Ebitda 0.50

FAQs

What is InflaRx N.V. share price today?

InflaRx N.V. (IFRX) share price today is $2

Can Indians buy InflaRx N.V. shares?

Yes, Indians can buy shares of InflaRx N.V. (IFRX) on Vested. To buy InflaRx N.V. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IFRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of InflaRx N.V. be purchased?

Yes, you can purchase fractional shares of InflaRx N.V. (IFRX) via the Vested app. You can start investing in InflaRx N.V. (IFRX) with a minimum investment of $1.

How to invest in InflaRx N.V. shares from India?

You can invest in shares of InflaRx N.V. (IFRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in IFRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in InflaRx N.V. shares
What is InflaRx N.V. 52-week high and low stock price?

The 52-week high price of InflaRx N.V. (IFRX) is $2.81. The 52-week low price of InflaRx N.V. (IFRX) is $1.17.

What is InflaRx N.V. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of InflaRx N.V. (IFRX) is 1.74

What is the Market Cap of InflaRx N.V.?

The market capitalization of InflaRx N.V. (IFRX) is $117.77M

What is InflaRx N.V.’s stock symbol?

The stock symbol (or ticker) of InflaRx N.V. is IFRX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top